• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Endocr Pract . COVID-19 may increase the risk of insulin resistance in adult patients without diabetes: A 6-month prospective study

tetano

Editor, Senior Moderator
Endocr Pract


. 2021 Apr 19;S1530-891X(21)00161-0.
doi: 10.1016/j.eprac.2021.04.004. Online ahead of print.
COVID-19 may increase the risk of insulin resistance in adult patients without diabetes: A 6-month prospective study


Mochuan Chen[SUP] 1 [/SUP], Bing Zhu[SUP] 2 [/SUP], Dong Chen[SUP] 3 [/SUP], Xingzhong Hu[SUP] 3 [/SUP], Xueqin Xu[SUP] 3 [/SUP], Wen-Jun Shen[SUP] 4 [/SUP], Chenchan Hu[SUP] 5 [/SUP], Jue Li[SUP] 6 [/SUP], Shen Qu[SUP] 7 [/SUP]



Affiliations

Abstract

Objective: During the coronavirus disease 2019 (COVID-19) pandemic, exploring insulin resistance and ?-cell activity is important for understanding COVID-19-associated new-onset diabetes. This study aimed to assess insulin sensitivity and fasting insulin secretion in COVID-19 patients without diabetes on admission and at 3 and 6 months after discharge.
Methods: This 6-month prospective study assessed data from the records of 64 patients without diabetes diagnosed with COVID-19 at Wenzhou Central Hospital, China. Each patient was followed up for 3 and 6 months after discharge. Repeated measures analysis of variance was used to investigate differences in multiple measurements of the same variable at different times. Linear regression analysis was performed to analyze the contributor for changes in triglyceride-glucose (TyG) index.
Results: Fasting C-peptide levels in patients at baseline were lower than the normal range (1.1-4.4 ?g/L). Compared with baseline, patients had significantly elevated fasting C-peptide levels (0.35?0.24 vs. 2.36?0.98 vs. 2.52?1.11 ?g/L, P?0.001), HOMA-CP (0.42, IQR 0.36-0.62 vs. 2.54, IQR 1.95-3.42 vs. 2.90, IQR 2.02-4.23, P?0.001) and TyG indexes (8.57?0.47 vs. 8.73?0.60 vs. 8.82?0.62, P=0.006), and decreased fasting glucose levels (5.84?1.21 vs. 4.95?0.76 vs. 5.40?0.68 mmol/L, P=0.003) during the 3 and 6-month follow-up. Male gender [? (95%CI): -0.312 (-0.590, -0.034)], age [0.012 (0.001, 0.023)], interferon-alfa treatment during hospitalization [0.540 (0.029, 1.051)], and changes in TC [0.217 (0.069, 0.366)] and HDL [-0.477 (-0.881, -0.074)] levels were significantly associated with changes in the TyG index.
Conclusions: Our study provided the first evidence that COVID-19 may increase the risk of insulin resistance in patients without diabetes.

Keywords: Coronavirus disease 2019 (COVID-19); Triglyceride-glucose (TyG) index; insulin resistance; insulin secretion.
 
Back
Top Bottom